NCT05513703 2025-10-24
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie
Phase 2 Terminated
AbbVie
SWOG Cancer Research Network